Stocks Health care ALKS
NASDAQ · Health careAlkermes plc. (ALKS)
Alkermes plc. brought in $1.8B of revenue over the twelve months to September 30, 2026, up 15.3% from a year earlier. It posted a net loss of $351K. Operating cash flow minus capital spending left $480.3M of free cash flow in fiscal 2025. At September 30, 2026 it held $631.3M in cash against $1.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Alkermes plc.
- Net worth
- Alkermes plc. has a market value (market cap) of $7.7B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.5B (-5.2% year on year), with net income of $241.7M. Over the 12 months to September 30, 2026: revenue $1.8B, net loss $351K.
- Cash flow
- In fiscal 2025 operations brought in $520.8M of cash; after $40.4M of capital spending, free cash flow was $480.3M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alkermes plc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Alkermes plc. does
Alkermes plc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALKS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.5B | $241.7M | $1.43 | $480.3M |
| 2024 | $1.6B | $367.1M | $2.17 | $405.6M |
| 2023 | $1.7B | $355.8M | $2.10 | $353.3M |
| 2022 | $1.1B | -$158.3M | -$0.97 | -$17.2M |
| 2021 | $1.2B | -$48.2M | -$0.29 | $73.7M |
| 2020 | $1B | -$110.9M | -$0.70 | $40.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALKS ranks in Health care
Latest SEC filings
What Alkermes plc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 22% to $480.1M versus the same quarter last year; diluted EPS $0.09 versus $0.49.
- November 3, 2026
- September 21, 2026
- September 16, 2026Executive or director change8-KAlkermes appointed Anne C. Whitaker to its board of directors and expanded the board from 10 to 11 members.
- August 12, 2026
- August 3, 2026
- July 28, 2026
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 27% to $496M versus the same quarter last year; diluted EPS $0.00 versus $0.52.
- July 28, 2026
- July 8, 2026
What is ALKS worth? A DCF from its reported cash flow
Insider trades
What the people running Alkermes plc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Soldpre-planned (10b5-1) | 2,035 | $94K |
| October 8, 2026 | Reed JoshuaSVP, Chief Financial Officer | Exercised options | 9,164 | - |
| October 8, 2026 | Reed JoshuaSVP, Chief Financial Officer | Shares withheld for tax | 4,069 | $163.2K |
| October 2, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Soldpre-planned (10b5-1) | 2,034 | $83.5K |
| September 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Soldpre-planned (10b5-1) | 2,034 | $97.7K |
| September 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Exercised options | 5,000 | $123K |
| September 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Soldpre-planned (10b5-1) | 9,000 | $422.9K |
| August 17, 2026 | Nichols Christian ToddSVP, Chief Commercial Officer | Soldpre-planned (10b5-1) | 6,912 | $340K |
Who owns ALKS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13G, passive with 3 related filers | 6.1% | February 17, 2026 |
| Vanguard Portfolio Management13G, passive | 5.8% | April 28, 2026 |
| Vanguard Capital Management13G, passive | 5.21% | April 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 424 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 29,235,739 | +921,329 |
| Baker Bros. Advisors LP | 10,012,267 | 0 |
| Vanguard Portfolio Management LLC | 9,490,818 | -20,294 |
| State Street Corp | 9,160,575 | -304,711 |
| Vanguard Capital Management LLC | 7,515,025 | +87,628 |
| Renaissance Technologies LLC | 6,460,928 | +300,500 |
| Geode Capital Management, LLC | 4,477,876 | +295,609 |
| Dimensional Fund Advisors LP | 4,194,873 | -327,505 |
| Deep Track Capital, LP | 4,000,000 | +409,677 |
| American Century Companies Inc | 3,954,239 | -2,117,864 |
| Holocene Advisors, LP | 3,601,472 | +1,284,146 |
| Commodore Capital LP | 3,000,000 | -1,200,000 |
| Wellington Management Group Llp | 2,814,804 | -155,362 |
| Primecap Management Co | 2,528,680 | -11,310 |
| First Trust Advisors LP | 2,421,016 | -547,769 |
| Charles Schwab Investment Management Inc | 2,335,117 | +98,361 |
| Nuveen, LLC | 2,324,197 | -136,372 |
| Norges Bank | 2,156,814 | new |
| Bvf Inc | 2,154,704 | +154,704 |
| Goldman Sachs Group Inc | 2,023,984 | +141,806 |
Insiders
15 insiders reported holding 2,328,578 shares in total, about $107.4M at the last price.
| Holder | Shares |
|---|---|
| Pops Richard FDirector and CEO, Alkermes plc, Director | 1,377,740 |
| Jackson Blair CurtisEVP, Chief Operating Officer | 241,308 |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | 219,353 |
| Cooke ShaneDirector | 106,679 |
| Nichols Christian ToddSVP, Chief Commercial Officer | 102,193 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | 65,389 |
| Mckeon Brian PDirector | 38,536 |
| Gaynor RichardDirector | 35,751 |
| Wilson Frank AndersDirector | 35,751 |
| Laurencin Cato TDirector | 33,769 |
Questions about ALKS
What does Alkermes plc. do?
Alkermes plc. is a company in the Health care sector, listed on NASDAQ as ALKS. Its shares trade on NASDAQ under the ticker ALKS.
What is Alkermes plc.'s net worth?
Alkermes plc. has a market value (market cap) of $7.7B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alkermes plc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $351K on revenue of $1.8B.
How much revenue does Alkermes plc. make?
Over the twelve months to September 30, 2026 Alkermes plc. reported revenue of $1.8B. That is 15.3% more than a year earlier.
When did Alkermes plc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Alkermes plc.'s next earnings report?
Alkermes plc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALKS with
Follow ALKS
Get an email when Alkermes plc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alkermes plc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.